round perform
initi coverag abbvi inc buy rate
target price estim non-
gaap ep earn multipl
upsid potenti expect top-lin
revenu increas
estim base follow factors- continu
growth humira imbruvica creon duodopa launch
hcv product mavyret strong revenu growth
plan to- invest capit within
current evalu addit expans facil
acceler pension fund well enhanc
contribut select not-for-profit organ
support initi puerto rico rebuild effort
children healthcar access program chariti support
saw strong result sever pivot trial includ
data three phase studi upadacitinib ra four
phase studi risankizumab psoriasi murano
studi venclexta relapsed/refractori cll
plan launch major label expans
venclexta relapsed/refractori cll well elagolix
endometriosi late rova-t begin
contribut growth launch next-
gener immunolog asset risankizumab upadacitinib
expect regulatori decis elagolix
second quarter growth outlook provid
follow approv
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
total revenu quarter increas
compar total revenu
 increas
compar total intern revenu
increas compar
previou year quarter
net incom quarter compar
basi dilut ep
quarter
imbruvica revenu expect
hcv sale expect due
success launch mavyret
venclexta sale expect
submit regulatori applic
venclexta plu rituxan relpased/refractori cll
look forward expand venclexta
abbvi ytd stock perform roa
ttm roe ttm oper margin
averag price-to-earnings present
focus deliv strong financi result
creat invest pipelin ensur strong
sustain growth busi long time period
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date may ex-dividend date apr last split factor new per old n/a last split date n/atrad inform inc april
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
incom statement item total gross research develop sell gener administr sg oper oper profit interest incom special charges- interest incom minor interest- incom incom net incom outstand dilut ep dilut ep dividend paid per share actual annual estim annual actual quarterli abbvi inc april
 market account receivable- receivable- total prepaid current assets- total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer revenues- current liabilities- total current long-term debt- defer incom taxes- non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item abbvi inc april
oper cash flow increas compar due improv result
oper result revenu growth improv oper earn decreas
flow invest activ compar invest cash
flow year includ capit expenditur payment made acquisit
invest partial off-set net sale matur invest secur total
flow financ activ compar dividend
payment compar increas cash dividend due
increas dividend rate
defer incom taxes- oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work capital- non- net continu net discontinu operations- net total oper invest activitiessal properti plant equipment- purchas properti plant acquisitions- net invest financ activitiesissu debt- issuanc capit stock- repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end basi total
revenu quarter
increas
compar
period
basi
gross margin ratio
ratio
result overview
inc incorpor april research-bas
biopharmaceut compani got separ
employe oper one busi segment
engag discoveri develop manufactur sale rang
pharmaceut product product gener sold world-wide
directli wholesal distributor govern agenc health care facil
specialti pharmaci independ retail abbvie-own
distribut center public warehous
product focus treat condit chronic auto immun
diseas rheumatolog gastroenterolog dermatolog oncolog
includ blood cancer virolog includ hepat viru hcv human
immunodefici viru hiv neurolog disord parkinson
diseas multipl sclerosi metabol diseas includ thyroid diseas
complic associ cystic fibrosi seriou health
offer product variou categori includ humira adalimumab
metabolics/hormon product endocrinolog product product
deliv strong financi result year adjust dilut ep
quarter increas compar
basi total revenu quarter increas
compar oper basi adjust net
revenu increas exclud favor impact foreign
total revenu increas
compar total intern revenu increas
compar previou year quarter
cog quarter increas compar
basi gross margin ratio
adjust gross margin ratio
result overview
sg expens quarter compar
basi sg expens net revenu adjust
sg expens net revenu
 expens quarter compar
basi expens net revenu adjust
expens reflect fund action support stage abbv
total oper expens quarter compar
total oper incom quarter decreas
compar basi oper margin
adjust oper margin
net interest expens quarter compar
incom tax expens compar
basi tax rate quarter adjust
tax rate
net incom quarter compar
basi dilut ep quarter
sinc incept consist deliv strong result total
revenu compar increas net
revenu due continu strength humira revenu growth
also support imbruvica key product includ creon
duodopa launch hcv product mavyret
total revenu increas compar
previou year total intern revenu increas
compar previou year
cog increas compar
gross margin percentag net revenu decreas
compar due intang asset impair charg
quarter decreas
compar
net incom
quarter
compar
basi dilut ep
quarter
result overview
also due unfavor impact higher intang asset amort
imbruvica profit share arrang gross margin
compar
sg expens compar sg
expens decreas net revenu compar
due continu leverag revenu growth partial off-set litig
reserv charg new product launch expens
 expens compar increas
expens due increas fund support compani emerg
mid late-stag pipelin asset impact post-acquisit
expens stemcentrx boehring ingelheim bi compound
increas develop mileston
total oper expens compar
total oper incom compar
interest expens compar
effect incom tax rate compar
increas tax rate due estim tax effect enact
tax cut job act net incom year compar
basi dilut ep year adjust dilut ep
reflect growth
plan make invest next five year capit
project also plan one-tim contribut
select charit organ enhanc non-
execut employe compens benefit repurchas
share
sg expens
decreas net
revenu
compar
compar
incom
compar
offer product variou categori includ humira adalimumab
metabolic/hormon product endocrinolog product product
portfolio product includ broad line therapi address
world complex seriou diseas
humira biolog therapi administ subcutan inject
approv treat autoimmun diseas rheumatoid arthriti
non-infecti intermedi posterior panuv juvenil idiopath
arthriti north america european union
total revenu humira compar previou
year quarter total revenu year increas
compar
increas revenu due market growth across therapeut
categori geographi well favor price certain geographi
revenu compar total
intern revenu compar
oncolog product abbvi oncolog product includ imbruvica
venclexta target complex difficult-to-treat
veclexta approv treat peopl cll delet
receiv least one prior treatment first fda-approv treatment
target b-cell lymphoma protein support cancer cell
growth overexpress mani patient cll
imbruvica oral once-daili therapi inhibit protein call
bruton tyrosin kinas btk approv treatment patient
chronic lymphocyt leukemia cll mantl cell lymphoma mcl receiv
least one prior therapi patient relapsed/refractori margin zone
humira
compar
previou year
year increas
compar
imbruvica revenu
year increas
compar
imbruvica total revenu quarter increas
compar imbruvica revenu year increas
compar
increas revenu due continu penetr imbruvica
first-lin treatment patient cll well favor price
imbruvica total revenu increas
compar total revenu quarter
total intern revenu quarter increas
compar
virolog product virolog product address unmet need
patient live hcv virolog product includ hcv product
viekira mavyret kaletra norvir synagi
abbvi hcv product viekira pak all-or short-cours interferon-fre
therapi without ribavirin treatment adult patient
genotyp chronic hcv includ compens cirrhosi europ
hcv treatment market viekirax exviera approv use
patient genotyp genotyp hcv technivi also
approv use combin ribavirin treatment adult
genotyp hcv infect
abbvi hcv product mavyret approv eu maviret
treatment patient chronic hcv genotyp infect without cirrhosi
compens cirrhosi child-pugh also indic
treatment adult patient hcv genotyp infect previous
treat regimen contain hcv inhibitor
proteas inhibitor pan-genotyp treatment
patient without cirrhosi new treatment
hcv total revenu quarter increas compar
previou year quarter total revenu year decreas
compar decreas revenu due
market contract lower market share price eros viekira
hcv total revenu
quarter increas
compar previou
year quarter total
revenu year
decreas
compar
hcv total revenu quarter year
compar total intern revenu quarter
year compar
kaletra also market aluvia emerg market prescript
medicin contain two proteas inhibitor lopinavir ritonavir
kaletra use medic treatment maintain
viral suppress peopl
kaletra total revenu quarter decreas
compar previou year quarter total revenu year decreas
compar due lower market share
due increas competit hiv market
kaletra total revenu decreas compar
previou year total intern revenu year decreas
compar
norvir proteas inhibitor indic combin
antiretrovir agent treatment infect
synagi product market outsid unit state
protect at-risk infant sever respiratori diseas caus rsv
synagiss total revenu quarter increas compar
previou year quarter total revenu year increas
compar
metabolics/hormon product metabol hormon product target
number condit includ testosteron defici due certain underli
condit exocrin pancreat insuffici hypothyroid product
includ androgel creon synthroid right sell androgel
creon synthroid
androgel testosteron gel testosteron replac therapi male
diagnos symptomat low testosteron due certain underli
condit avail two strength
quarter decreas
compar previou
year quarter total
revenu year
decreas
compar
quarter increas
compar previou
year quarter total
revenu year
increas
compar
quarter decreas
compar previou
year quarter
androgel total revenu quarter decreas
compar previou year quarter total revenu year decreas
compar
creon pancrelipas pancreat enzym therapi exocrin pancreat
insuffici condit occur patient cystic fibrosi chronic
pancreat sever condit
creon total revenu quarter increas
increas compar
increas due continu market growth higher market share creon
maintain market leadership pancreat enzym market
synthroid levothyroxin sodium tablet usp use treatment
hypothyroid sythroid total revenu quarter
increas compar
endocrinolog product abbvi endocrinolog product lupron also
market lucrin lupron depot product palli treatment
advanc prostat cancer treatment endometriosi central precoci
puberti preoper treatment patient anemia caus
uterin fibroid lupron approv daili subcutan inject one-
month three-month four-month six-month intramuscular inject
quarter increas
compar previou
year quarter
lupron total revenu quarter increas compar
previou year quarter total revenu year compar
total revenu compar previou
year total intern revenu compar
product product includ duopa duodop anesthesia
product zinbryta
duodopa levodopa-carbidopa intestin gel treatment
advanc parkinson diseas market duopa duodopa
outsid
duodopa total revenu quarter increas
compar previou year quarter total revenu year increas
compar increas revenu
due market penetr geograph expans
duodopa total revenu increas compar
previou year quarter total revenu year increas
compar
duodopa total intern revenu quarter increas
compar previou year quarter total revenu year
increas compar
anesthesia product sevofluran sold trademark ultan
sevoran anesthesia product sell world-wide human
sevofluran total revenu quarter decreas
compar previou year quarter total revenu year
decreas compar
sevofluran total revenu decreas compar
previou year quarter total revenu year decreas
compar
sevofluran total intern revenu quarter decreas
compar previou year quarter total revenu year
decreas compar
zinbryta once-monthli self-administ subcutan treatment
relaps form multipl sclerosi ms approv fda
may european commiss juli due risk
seriou liver damag use zinbryta restrict adult patient
relaps form ms inadequ respons least two
diseas modifi therapi dmt treatment
dmt contraind otherwis unsuit
quarter increas
compar previou
year quarter
revenu quarter
decreas
compar
previou year
summar transit signific program phase
develop phase develop well develop signific
phase registr program expect multipl phase
program transit phase program next twelv month
pipelin current includ compound indic
clinic develop individu collabor licens
agreement focus medic specialti immunolog
oncolog neurolog along target invest cystic fibrosi
abbvi late-stag pipelin strong across sever therapeut area
produc consist stream innov medicin total revenu
new oncolog virolog neurosci product launch sinc
total
announc posit result phase select-
monotherapi clinic trial evalu upadacitinib
monotherapi treatment patient moder sever rheumatoid
arthriti adequ respond treatment methotrex
result show week treatment one-daili dose
upadacitinib mg mg met studi primari endpoint
low diseas activ versu continu prior stabl
methotrex therapi dose also achiev rank key
safeti profil upadacitinib consist previous report
phase select clinic trial phase studi new safeti
signal detect expect data two addit
registr studi first half support regulatori
submiss second half
januari fda grant breakthrough therapi design
upadacitinib adult patient moder sever atop dermat
candid system therapi
announc result immhanc studi fourth pivot
clinic trial evalu risankizumab investig il-
inhibitor treatment patient moder sever
plaqu psoriasi result show risankizumab met co-
primari rank secondari endpoint studi
week patient receiv risankizumab achiev complet
skin clearanc pasi vs placebo static physician global
assess spga score clear almost clear skin achiev
risankizumab patient compar placebo patient
among patient achiev clear almost clear skin week
patient maintain respons one year compar
switch placebo week
posit result
monotherapi
treatment patient
moder sever
rheumatoid arthriti
adequ
respond treatment
methotrex
risankizumab safeti profil immhanc consist previous
report phase clinic trial new safeti signal detect across
phase program plan submit applic regulatori
approv first half risankizumab develop
collabor boehring ingelheim
januari fda approv imbruvica treatment
patient relapsed/refractori margin zone lymphoma mzl
requir system therapi receiv least one prior
indic approv acceler approv base overal
respons rate orr continu approv may conting upon
verif descript clinic benefit confirmatori trial
august fda approv imbruvica treatment adult
patient chronic graft-versus-host-diseas cgvhd failur one
line system therapi
decemb announc phase innov clinic
trial evalu imbruvica combin rituximab patient
untreat treatment-nav previously-tr waldenstrm
macroglobulinemia wm met primari endpoint first
treatment approv newli previously-tr patient wm
februari initi phase clinic trial studi safeti
efficaci venetoclax combin azacitidin untreat
elderli acut myeloid leukemia aml inelig standard
may initi phase clinic trial evalu
venetoclax co-administ low dose cytarabin ldac
improv overal surviv os versu ldac placebo treatment nave
subject aml
announc
phase innov
imbruvica
combin
rituximab patient
untreat
treatment-nav
wm met primari
septemb announc result phase
murano clinic trial evalu venetoclax tablet combin
rituxan met primari endpoint prolong progression-fre surviv
compar bendamustin combin rituxan patient
snda fda venclexta venetoclax combin rituxan
patient relaps refractori cll
januari submit snda venclexta monotherapi
patient cll relaps refractori b-cell receptor
februari initi phase clinic trial evalu
efficaci rovalpituzumab tesirin rova-t mainten therapi
follow first-lin platinum base chemotherapi particip
april initi phase clinic trial evalu rova-t
compar topotecan subject advanc metastat sclc
high level delta-lik protein first diseas progress
follow front-lin platinum-bas chemotherapi
novemb present result trial
mafodotin investig antibodi drug conjug
target epiderm growth factor receptor egfr alon combin
temozolomid tmz subject recurr glioblastoma
result studi fail meet primari
endpoint overal surviv submit regulatori
applic recurr gbm
combin tmz perform better
lomustin tmz posit trend overal surviv observ
submit snda
monotherapi patient
cll
relaps
refractori b-cell
result
fail meet
primari endpoint
overal surviv
applic
recurr gbm
file recurr gbm base data phase
trial evalu safeti efficaci
combin tmz subject newli diagnos gbm egfr
amplif on-going
april announc two phase studi evalu
veliparib investig oral poli adenosin diphosphate-ribos
polymeras parp inhibitor combin chemotherapi
meet primari endpoint
studi evalu veliparib combin carboplatin
paclitaxel patient squamou non-smal cell lung cancer nsclc
squamou non-smal cell lung cancer breast cancer ovarian
februari european committe medicin product
human use chmp grant posit opinion shorter week
treatment viekirax ombitasvir/paritaprevir/ritonavir tablet exviera
dasabuvir tablet option previous untreat adult patient
genotyp chronic hcv minim moder fibrosi
juli european commiss grant market author
adult hcv infect across major genotyp
august fda approv mavyret glecaprevir/pibrentasvir
treatment patient chronic hcv genotyp infect without
cirrhosi compens cirrhosi child-pugh
mavyret also indic treatment adult patient hcv
genotyp infect previous treat regimen
contain hcv inhibitor proteas inhibitor
august fda
treatment
patient chronic
cirrhosi
octob
elagolix fda
manag
endometriosi
septemb submit new drug applic fda
elagolix investig oral administ gonadotropin releas
hormon gnrh antagonist evalu manag
endometriosi associ pain
octob grant prioriti review elagolix fda
manag endometriosi associ pain novemb
announc detail result two replic phase extens
studi evalu long-term efficaci safeti elagolix
evalu manag endometriosi associ pain
decemb announc strateg decis close
sonar studi phase clinic trial evalu effect
investig compound atrasentan progress kidney diseas
patient stage chronic kidney diseas type diabet
ad standard care
on-going monitor renal event observ studi reveal
consider fewer endpoint expect time analysi
affect abil test sonar studi hypothesi therefor
determin justifi continu particip patient
studi decis close sonar studi earli relat
safeti concern
imbruvica revenu
expect
hcv sale
expect
due
success launch
dilut ep expect rais
adjust ep guidanc rang
total revenu expect sale growth
expect revenu expect
year
imbruvica revenu expect hcv sale
expect due success launch
expect
non-gaap tax rate
expect
expect
increas gradual
next five year
gross margin
percentag net
revenu decreas
compar
guidanc conclus
venclexta revenu expect creon sale
growth expect androgel sale expect
synagi lupron synthroid sale expect flat
duodopa sale expect zinbryta sale
expect less due label chang competit
non-gaap gross margin expect expens expect
sale due increas fund late-stag pipelin
continu progress mid-stag program sg expens expect
sale oper margin expect net interest
expect
non-gaap tax rate expect expect
increas gradual next five year lower tax rate
expect due one-tim benefit time phase-in
provis new law certain foreign subsidiari
focus deliv strong financi result creat invest
pipelin ensur strong sustain growth busi long
total revenu year increas dilut ep
increas revenu due continu strength
humira revenu growth relat imbruvica key product
includ creon duodopa launch hcv product mavyret
gross margin percentag net revenu decreas
compar effect tax rate
plan make invest next five year capit project
gener cash flow oper util
enhanc pipelin licens collabor activ abbvi
paid cash dividend stockhold repurchas share
open market
abbvi ytd stock perform roa ttm roe
ttm oper margin
non- reconcili
non- reconcili
non- reconcili
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
revenu growth compar
ep growth compar
gross margin decreas compar due increas cog
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth abbvi inc april
mrqgross mrqcog mrqsg mrqnet mrqr sale abbvi inc april
invest flow
sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqcapex salescap ex salesfre mrqreturn mrq ratio growth yoy oper growth yoy free growth yoy abbvi inc april
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item abbvi inc april
balanc sheet ratio
outstand equival market properti plant properti plant issuanc prefer issuanc chang abbvi inc april
price-to-earnings averag
price-to-earnings went averag present januari price-to-earnings went average
stdev
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form richard laura thoma henri roxann glenn institut holdersholdershar report outvaluecapit research global vanguard group inc northern trust america geod capit manag capit world state mutual automobil insur top mutual fund holdersholdersharesd report outvalueinvest compani vanguard total stock market capit incom builder capit world growth incom vanguard growth fund america spdr etf amcap vanguard institut fund-institut american mutual fund competit
develop announc result phase studi evalu rovalpituzumab tesirin rova-t third-lin treatment patient relapsed/refractori small cell lung cancermarch announc seek acceler approv rova-t third-lin relapsed/refractori small cell lung cancer sclc rova-t demonstr singl agent respons advanc sclc patient on-going phase studi meru taho continu investig rova-t first- second-lin sclc safeti data triniti studi consist previous report studi rova-t full data submit american societi clinic oncolog annual meet announc posit top-line result second phase studi evalu investig elagolix women uterin fibroidsmarch announc phase elari uf-ii studi elagolix met primari endpoint result second two pivot phase studi demonstr month six elagolix mg twice daili combin low-dos hormon add-back therapi estradiol mg norethindron acet mg reduc heavi menstrual bleed percent women uterin fibroid achiev clinic respons compar placebo percent measur alkalin hematin method announc global strateg collabor develop potenti new treatment alzheim diseas tau-rel neurodegen diseasesfebruari inc announc enter exclus strateg collabor option agreement develop commerci vector antibodi direct tau treatment alzheim diseas neurodegen diseas collabor combin monoclon antibodi expertis global clinic develop commerci capabl voyag gene therapi platform expertis enabl gener adeno-associ viral aav vector treatment neurodegen diseas upadacitinib grant breakthrough therapi design food drug administr atop dermatitisjanuari announc fda grant breakthrough therapi design investig once-daili oral inhibitor upadacitinib adult patient moder sever atop dermat candid system therapi breakthrough therapi design support posit previous announc inseptemb andmark therapi design grant investig treatment sinc compani incept upadacitinib approv regulatori author safeti efficaci establish inc april
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
perform vs
sale growth
vs industri
gross margin vs
industri averag
oper margin
vs industri
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit abbvi inc april
consensu view analyst trend stock
less
compar
compar
 average
abbv avgfive-year growth forecast usdgrowth high day day day estim comparisonabbvindustri avg avgprice/earn yield abbvi inc april
consensu view analyst trend stock
averag earn estim
current quarter
sale growth estim
current quarter
growth forecast less
compar
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningspeg ratioconsensu ep day day day day ep last last last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate abbvi inc april
incom statement
result
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
januari stock price went end januari
stock price present trade fell mid march
stock shown upward trend sinc april fell januari decreas march
week rang stock
stock price trade around start increas
went went
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
